EA
IBRX icon

Emerald Acquisition’s ImmunityBio IBRX Stock Holding History

Emerald Acquisition’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$181K Sell
23,224
-13,360
-37% -$99.8K ﹤0.01% 2709
2016
Q2 		$228K Buy
+36,584
New +$284K ﹤0.01% 2700

Other funds holding IBRX

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Acquisition's IBRX Position: Q3 2016 in Review

Emerald Acquisition reduced its ImmunityBio (IBRX) stake by 37% in Q3 2016, selling an estimated $99.8K and leaving 23,224 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

Emerald Acquisition first reported a position in IBRX in Q2 2016 and has held it in 2 quarters since. The position peaked at $228K in Q2 2016. 63 funds tracked by Wall St. Rank hold IBRX as of Q3 2016.

  • Emerald Acquisition held 23,224 shares of ImmunityBio worth $181K as of Q3 2016.
  • Emerald Acquisition sold 13,360 ImmunityBio shares in Q3 2016, an estimated $99.8K.
  • ImmunityBio made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2709 holding.
  • Emerald Acquisition first reported a position in ImmunityBio in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's ImmunityBio position peaked at $228K in Q2 2016.
  • 63 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.